However, as per recent meta-analysis published in 2020, achieving p-CR following neoadjuvant chemotherapy (NACT) is correlated with improved event free survival and OS particularly in HER2 +ve and triple negative breast cancer [24]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.